| Enumerate all the diseases against which vaccines are currently available (DNB 1993/2)15 | General | 1993 |
| Immunization schedule basis in child suffering from AIDS (DNB 1994/1)15 | General | 1994 |
| Live vaccines used in pediatric age group (DNB 1995/1)10 | General | 1995 |
| Adverse reactions that may occur following use of vaccines included in the National Immunization Schedule in India (DNB 1995/2)10 | General | 1995 |
| Describe briefly various adverse reactions following vaccinations and discuss their management (DNB 1997/2)25 | General | 1997 |
| Combination vaccine (DNB 1999/2)10, (DNB 2003/1)15 | General | 1999 |
| Cold Chain (DNB 2000/1)15, (DNB 2014/2)5 | General | 2000 |
| Vaccine Vial Monitor (DNB 2004/1)15 | General | 2004 |
| Describe the criteria or conditions to be considered for approving a 'newer' vaccine in an immunization program of a developing country (DNB 2008/1)10, (DNB 2013/2)10 | General | 2008 |
| Tabulate the various newer vaccines available to prevent respiratory disease in children, with their types, dosage schedule, route, important side effects and efficacy (DNB 2011/2)10 | General | 2011 |
| Define the following: (DNB 2013/1)2X5 a. Herd immunity b. Herd effect c. Vaccine immunogenicity d. Vaccine efficacy; and e. Vaccine effectiveness | General | 2013 |
| Salient differences between the National and IAP immunization schedule (DNB 2013/1)(5) | General | 2013 |
| Conjugate vaccines (DNB 2015/1)3, (DNB 2021/1)5 | General | 2015 |
| Pentavalent vaccines (DNB 2016/2)5 | General | 2016 |
| Adolescent vaccination (DNB 2017/1)5 | General | 2017 |
| Immunization in immunosuppressed children (DNB 2018/1)5 | General | 2018 |
| Adolescence immunization (DNB 2018/2)5 | General | 2018 |
| Classification of AEFI (DNB 2019/1)5 | General | 2019 |
| Combined vaccines (DNB 2019/1)5 | General | 2019 |
| Components of cold chain for immunisation in a hospital setting and its monitoring (DNB 2019/1)5 | General | 2019 |
| Different immunisation campaigns in India and their role in improving immunization coverage (DNB 2019/2)6 | General | 2019 |
| Future vaccines (DNB 2019/2)5 | General | 2019 |
| Immunization in adolescents (DNB 2020/2)5 | General | 2020 |
| Vaccine Hesitancy (DNB 2020/2)5, (DNB 2022/1)5, (DNB 2022/2)5 | General | 2020 |
| Assessment of causality in Adverse Events Following Immunization (DNB 2021/1)5 | General | 2021 |
| Vaccination in children with cancer on chemotherapy (DNB 2021/1)5 | General | 2021 |
| Dengue vaccines (DNB 2021/1)5 | General | 2021 |
| Types of Adverse Events Following Immunization (DNB 2021/2)5 | General | 2021 |
| Malaria vaccines (DNB 2021/2)4 | General | 2021 |
| National immunization schedule (DNB 2022/1)5 | General | 2022 |
| Adverse events following immunization (DCH 2024/1)5 | General | 2024 |
| Write briefly about different types of vaccine against rabies. Discuss various schedules of pre and post-exposure prophylaxis for rabies (DNB 2012/1)5+5 | Rabies Vaccine | 2012 |
| Anti-rabies vaccine - Different schedules, advantages of each schedule (DNB 2019/2)5 | Rabies Vaccine | 2019 |
| Post exposure prophylaxis for dog bite (DNB 2020/1)5 | Rabies Vaccine | 2020 |
| Monoclonal Antibodies in post exposure prophylaxis of Rabies (DNB 2021/1)5 | Rabies Vaccine | 2021 |
| Rabies post-exposure prophylaxis (DCH 2024/1)5 | Rabies Vaccine | 2024 |
| Varicella vaccine (DNB 2000/1)15 | Varicella Vaccine | 2000 |
| Complications of measles vaccination and management (DNB 1994/2)15 | Measles Vaccine | 1994 |
| MR vaccine (DNB 2023/2)5 | Measles Vaccine | 2023 |
| H.Influenza B vaccine (DNB 1998/2)15 | Hib Vaccine | 1998 |
| Tabulate the following details with regards to Rotavirus vaccine, HIB vaccine and Pneumococcal vaccine: (DNB 2009/2)10 a) Type of vaccine b) Dose c) Route d) Appropriate age of vaccination e) Justification of its usage f) Side effect and g) Drawback | Hib Vaccine | 2009 |
| Typhoid Vaccines (DNB 1997/1)15, (DNB 2019/1)5 | Typhoid Vaccine | 1997 |
| Typhoid conjugate vaccine (DNB 2020/1)5 | Typhoid Vaccine | 2020 |
| Hepatitis B immunization (DNB 1993/2)10 | Hepatitis B Vaccine | 1993 |
| Hepatitis B vaccine (DNB 1996/1)5, (DNB 1997/1)10 | Hepatitis B Vaccine | 1996 |
| Pneumococcal vaccine (DNB 1996/2)15 | Pneumococcal Vaccine | 1996 |
| Pneumococcal vaccine (DNB 2017/2)5, (DNB 2022/2)5, (DNB 2024/2)5 | Pneumococcal Vaccine | 2017 |
| Influenza Type B vaccine (DNB 1998/1)15 | Influenza Vaccine | 1998 |
| Current status of post-DPT vaccine encephalopathy (DNB 1993/1)15 | DPT Vaccine | 1993 |
| Discuss the aetiology, pathogenesis and prevention of pertussis in children. Write the differences in efficacy, duration of protection and adverse effects between whole cell and acellular pertussis vaccine (DNB 2014/1)6+4 | DPT Vaccine | 2014 |
| Difference between acellular and whole cell pertussis vaccine (DNB 2023/1)5 | DPT Vaccine | 2023 |
| Status of Polio vaccines (DNB 1993/1)15 | Polio Vaccine | 1993 |
| Discuss the current role, advantages and disadvantages of OPV and IPV in control and eradication of poliomyelitis in India (DNB 2011/1)4+6 | Polio Vaccine | 2011 |
| What is inactivated polio vaccine (IPV). What are the advantages and disadvantages of IPV over OPV? What is the schedule of IPV as recommended by IAP (DNB 2014/2)3+5+2 | Polio Vaccine | 2014 |
| VAPP (Vaccine Associated Paralytic Poliomyelitis) (DNB 2016/1)5 | Polio Vaccine | 2016 |
| Injectable polio vaccination schedules (DNB 2024/1)5 | Polio Vaccine | 2024 |
| Utility and controversy of HPV Vaccine (DNB 2010/1)5+5 | HPV Vaccine | 2010 |
| HPV vaccine (DNB 2015/1)4 | HPV Vaccine | 2015 |
| HPV vaccine-current status (DNB 2018/2)5 | HPV Vaccine | 2018 |
| Rota virus vaccine (DNB 2015/1)3 | Rota Virus Vaccine | 2015 |
| Rota virus vaccine- schedule, dosage, side effects (DNB 2017/1)5 | Rota Virus Vaccine | 2017 |
| Pneumococcal vaccines (DNB 2024/2)5 | Pneumococcal Vaccine | 2024 |